GAPVAC results presentation at ASCO 2018 (June 1-5) in Chicago, IL

| News

Results from the GAPVAC clinical trial will be presented at ASCO 2018! 

The oral presentation “GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma” by Lead Investigator Prof. Dr. Wolfgang Wick (University Hospital Heidelberg, Germany) will take place on June 1st during the Central Nervous System Tumors session (starting 2:45 pm CDT).

GAPVAC is an EU-funded consortium with the goal to establish an actively personalized vaccination approach in glioma treatment. The consortium integrates thirteen partners from industry and academia and is led by the biotech companies Immatics and BioNTech.
Visit and for more information.


Press Contact

Anja Heuer

Corporate Communications,
Immatics Biotechnologies GmbH

+49 89 540 415 606

Go back

We use cookies to ensure that we give you the best experience on our website.